Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)

被引：0

作者：

Powles, T. ^{[1
]}

Motzer, R. J. ^{[2
]}

George, D. J. ^{[3
]}

Jonasch, E. ^{[4
]}

Pal, S. ^{[5
]}

Tannir, N. M. ^{[4
]}

Signoretti, S. ^{[6
]}

Mai, T. H. ^{[7
]}

Scheffold, C. ^{[8
]}

Wang, E. ^{[9
]}

Aftab, D. T. ^{[10
]}

Escudier, B. ^{[11
]}

Choueiri, T. K. ^{[12
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[3] Duke Univ Med Ctr, Duke Canc Inst, Durham, NC USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[5] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA

[6] Brigham & Womens Hosp, Pathol, 75 Francis St, Boston, MA 02115 USA

[7] Ann Arbor Pharmacometr Grp, Pharmacometr, Ann Arbor, MI USA

[8] Exelixis Inc, Clin Dev, San Francisco, CA USA

[9] Exelixis Inc, Translat Med, San Francisco, CA USA

[10] Exelixis Inc, Execut Adm, San Francisco, CA USA

[11] Gustave Roussy, Med Oncol, Villejuif, France

[12] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

872P

引用

页数：2

共 50 条

[1] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC)
Gruellich, C.
Powles, T.
Motzer, R. J.
George, D. J.
Jonasch, E.
Pal, S. K.
Tannir, N. M.
Signoretti, S.
Mai, T. H.
Scheffold, C.
Wang, E.
Aftab, D. T.
Escudier, B. J.
Choueiri, T. K.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 201 - 201
[2] Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
Thomas Powles
Toni K. Choueiri
Robert J. Motzer
Eric Jonasch
Sumanta Pal
Nizar M. Tannir
Sabina Signoretti
Rajesh Kaldate
Christian Scheffold
Evelyn Wang
Dana T. Aftab
Bernard Escudier
Daniel J. George
BMC Cancer, 21
[3] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (vol 21, 904, 2021)
Powles, Thomas
Choueiri, Toni K.
Motzer, Robert J.
Jonasch, Eric
Pal, Sumanta
Tannir, Nizar M.
Signoretti, Sabina
Kaldate, Rajesh
Scheffold, Christian
Wang, Evelyn
Aftab, Dana T.
Escudier, Bernard
George, Daniel J.
BMC CANCER, 2021, 21 (01)
[4] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
Donskov, Frede
Motzer, Robert J.
Voog, Eric
Hovey, Elizabeth J.
Griillich, Carsten
Nott, Louise M.
Cuff, Katharine Ellen
Gil, Thierry
Jensen, Niels Viggo
Chevreau, Christine
Negrier, Sylvie
Depenbusch, Reinhard
Bergmann, Lothar
Cornelio, Izzy
Champsaur, Anne
Escudier, Bernard J.
Pal, Sumanta K.
Powles, Thomas
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
Bergmann, L.
Donskov, F.
Motzer, R. J.
Voog, E.
Hovey, E. J.
Gruellich, C.
Nott, L. M.
Cuff, K. E.
Gil, T.
Jensen, N., V
Chevreau, C.
Negrier, S.
Depenbusch, R.
Cornelio, I
Champsaur, A.
Escudier, B. J.
Pal, S. K.
Powles, T.
Choueiri, T. K.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 201
[6] Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
Cella, D.
Escudier, B.
Tannir, N.
Powles, T.
Donskov, F.
Peltola, K.
Schmidinger, M.
Heng, D.
Mainwaring, P.
Hammers, H.
Lee, J-L.
Rini, B. I.
Roth, B.
Baer, J.
Mangeshkar, M.
Scheffold, C.
Hutson, T.
Pal, S.
Motzer, J.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2016, 27
[7] Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC)
Powles, Thomas
Escudier, Bernard
Motzer, Robert J.
Tannir, Nizar M.
Scheffold, Christian
Aftab, Dana T.
Chouieri, Toni K.
BJU INTERNATIONAL, 2016, 118 : 4 - 4
[8] METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC)
Powles, Thomas
Escudier, Bernard
Mainwaring, Paul N.
Rini, Brian I.
Donskov, Frede
Hammers, Hans J.
Hutson, Thomas E.
Roth, Bruce
Peltola, Katriina
Lee, Jae Lyun
Heng, Daniel Y. C.
Schmidinger, Manuela
Borgman, Anne
Hessel, Colin
Scheffold, Christian
Schwab, Gisela
Tannir, Nizar M.
Motzer, Robert J.
Choueiri, Toni K.
BJU INTERNATIONAL, 2015, 116 : 19 - 19
[9] Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC)
Powles, Thomas
Motzer, Robert J.
Escudier, Bernard J.
Pal, Sumanta K.
Kollmannsberger, Christian K.
Pikiel, Joanna
Gurney, Howard
Rha, Sun Young
Park, Se Hoon
Geertsen, Poul F.
Gross-Goupil, Marine
Grande, Enrique
Suarez, Cristina
Arroyo, Alan M.
Dean, Mark
George, Daniel
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
Schmidinger, M.
Tannir, N. M.
Powles, T.
Escudier, B. J.
Donskov, F.
Gruenwald, V
Sternberg, C. N.
Schoffski, P.
Szczylik, C.
Peltola, K. J.
Nosov, D.
Melichar, B.
Clary, D. O.
Scheffold, C.
Motzer, R. J.
Choueiri, T. K.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 200

← 1 2 3 4 5 →